Aurélien Venara1,2,3, Emilie Duchalais4,5, Anne Dariel4,6, Philippe Aubert4, Tony Durand4, Guillaume Meurette4,5,6, Malvyne Rolli-Derkinderen4,6, Antoine Hamy7,8, Michel Neunlist9,10,11. 1. TENS - The enteric nervous system in gut and brain disorders, INSERM U1235, 44093, Nantes, France. auvenara@yahoo.fr. 2. L'UNAM, University of Angers, Angers, France. auvenara@yahoo.fr. 3. Department of Digestive and Endocrinal Surgery, University Hospital of Angers, 4 rue Larrey, 49933, Angers Cedex 9, France. auvenara@yahoo.fr. 4. TENS - The enteric nervous system in gut and brain disorders, INSERM U1235, 44093, Nantes, France. 5. CHU Nantes, Hotel Dieu, Institut des maladies de l'Appareil Digestif, 44093, Nantes, France. 6. L'UNAM, University of Nantes, Nantes, France. 7. L'UNAM, University of Angers, Angers, France. 8. Department of Digestive and Endocrinal Surgery, University Hospital of Angers, 4 rue Larrey, 49933, Angers Cedex 9, France. 9. TENS - The enteric nervous system in gut and brain disorders, INSERM U1235, 44093, Nantes, France. Michel.neunlist@univ-nantes.fr. 10. CHU Nantes, Hotel Dieu, Institut des maladies de l'Appareil Digestif, 44093, Nantes, France. Michel.neunlist@univ-nantes.fr. 11. L'UNAM, University of Nantes, Nantes, France. Michel.neunlist@univ-nantes.fr.
Abstract
BACKGROUND: Postoperative ileus (POI) is observed in 20-30% of patients undergoing colorectal cancer surgery, despite enhanced recovery programs (ERPs). Cyclooxygenase (COX)-2 is identified as a key enzyme in POI, but other arachidonic acid pathway enzymes have received little attention despite their potential as selective targets to prevent POI. The objectives were to compare the expression of arachidonic acid metabolism (AAM) enzymes (1) between patients who underwent colorectal cancer surgery and followed an ERP or not (NERP), (2) and between ERP patients who experimented POI or not and (3) to determine the ability of antagonists of these pathways to modulate contractile activity of colonic muscle. METHODS: This was a translational study. Main outcome measures were gastrointestinal motility recovery data, mRNA expressions of key enzymes involved in AAM (RT-qPCR) and ex vivo motility values of the circular colon muscle. Twenty-eight prospectively included ERP patients were compared to eleven retrospectively included NERP patients that underwent colorectal cancer surgery. RESULTS: ERP reduced colonic mucosal COX-2, microsomal prostaglandin E synthase (mPGES1) and hematopoietic prostaglandin D synthase (HPGDS) mRNA expression. mPGES1 and HPGDS mRNA expression were significantly associated with ERP compliance (respectively, r2 = 0.25, p = 0.002 and r2 = 0.6, p < 0.001). In muscularis propria, HPGDS mRNA expression was correlated with GI motility recovery (p = 0.002). The pharmacological inhibition of mPGES1 increased spontaneous ex vivo contractile activity in circular muscle (p = 0.03). CONCLUSION: The effects of ERP on GI recovery are correlated with the compliance of ERP and could be mediated at least in part by mPGES1, HPGDS and COX-2. Furthermore, mPGES1 shows promise as a therapeutic target to further reduce POI duration among ERP patients.
BACKGROUND: Postoperative ileus (POI) is observed in 20-30% of patients undergoing colorectal cancer surgery, despite enhanced recovery programs (ERPs). Cyclooxygenase (COX)-2 is identified as a key enzyme in POI, but other arachidonic acid pathway enzymes have received little attention despite their potential as selective targets to prevent POI. The objectives were to compare the expression of arachidonic acid metabolism (AAM) enzymes (1) between patients who underwent colorectal cancer surgery and followed an ERP or not (NERP), (2) and between ERP patients who experimented POI or not and (3) to determine the ability of antagonists of these pathways to modulate contractile activity of colonic muscle. METHODS: This was a translational study. Main outcome measures were gastrointestinal motility recovery data, mRNA expressions of key enzymes involved in AAM (RT-qPCR) and ex vivo motility values of the circular colon muscle. Twenty-eight prospectively included ERP patients were compared to eleven retrospectively included NERP patients that underwent colorectal cancer surgery. RESULTS: ERP reduced colonic mucosalCOX-2, microsomal prostaglandin E synthase (mPGES1) and hematopoietic prostaglandin D synthase (HPGDS) mRNA expression. mPGES1 and HPGDS mRNA expression were significantly associated with ERP compliance (respectively, r2 = 0.25, p = 0.002 and r2 = 0.6, p < 0.001). In muscularis propria, HPGDS mRNA expression was correlated with GI motility recovery (p = 0.002). The pharmacological inhibition of mPGES1 increased spontaneous ex vivo contractile activity in circular muscle (p = 0.03). CONCLUSION: The effects of ERP on GI recovery are correlated with the compliance of ERP and could be mediated at least in part by mPGES1, HPGDS and COX-2. Furthermore, mPGES1 shows promise as a therapeutic target to further reduce POI duration among ERP patients.
Authors: U O Gustafsson; M J Scott; W Schwenk; N Demartines; D Roulin; N Francis; C E McNaught; J Macfie; A S Liberman; M Soop; A Hill; R H Kennedy; D N Lobo; K Fearon; O Ljungqvist Journal: World J Surg Date: 2013-02 Impact factor: 3.352
Authors: Sjoerd H W van Bree; Willem A Bemelman; Markus W Hollmann; Aeilko H Zwinderman; Gianluca Matteoli; Shaima El Temna; Frans O The; Malaika S Vlug; Roelof J Bennink; Guy E E Boeckxstaens Journal: Ann Surg Date: 2014-04 Impact factor: 12.969
Authors: T C van den Heijkant; L M M Costes; D G C van der Lee; B Aerts; M Osinga-de Jong; H R M Rutten; K W E Hulsewé; W J de Jonge; W A Buurman; M D P Luyer Journal: Br J Surg Date: 2014-12-18 Impact factor: 6.939
Authors: J Gong; Z Xie; T Zhang; L Gu; W Yao; Z Guo; Y Li; N Lu; W Zhu; N Li; J Li Journal: Aliment Pharmacol Ther Date: 2016-02-15 Impact factor: 8.171
Authors: Jean F Hamel; Charles Sabbagh; Arnaud Alves; Jean M Regimbeau; Timothée Vignaud; Aurélien Venara Journal: Sci Rep Date: 2021-04-01 Impact factor: 4.379